These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10531568)

  • 1. Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.
    Pession A; Prete A; Locatelli F; Bella S; Melchionda F; Garaventa A; Burnelli R; Paolucci G
    Med Pediatr Oncol; 1999 Nov; 33(5):450-4. PubMed ID: 10531568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
    Weaver CH; Bensinger WI; Appelbaum FR; Lilleby K; Sandmaier B; Brunvand M; Rowley S; Petersdorf S; Rivkin S; Gooley T
    Bone Marrow Transplant; 1994 Nov; 14(5):813-9. PubMed ID: 7889015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
    Hawkins D; Barnett T; Bensinger W; Gooley T; Sanders J
    Med Pediatr Oncol; 2000 May; 34(5):328-37. PubMed ID: 10797354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
    Kamani N; August CS; Bunin N; Leahey A; Bayever E; Goldwein J; Zusman J; Evans AE; Angio GD
    Bone Marrow Transplant; 1996 Jun; 17(6):911-6. PubMed ID: 8807093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults.
    Papadopoulos KP; Garvin JH; Fetell M; Vahdat LT; Garrett TJ; Savage DG; Balmaceda C; Bruce J; Sisti M; Isaacson S; De LaPaz R; Hawks R; Bagiella E; Antman KH; Hesdorffer CS
    Bone Marrow Transplant; 1998 Oct; 22(7):661-7. PubMed ID: 9818693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors.
    Papadopoulos KP; Balmaceda C; Fetell M; Kaufman E; Vahdat LT; Bruce J; Sisti M; Isaacson S; De LaPaz R; Savage DG; Troxel A; Antman KH; Hesdorffer CS
    J Neurooncol; 1999 Sep; 44(2):155-62. PubMed ID: 10619499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
    Demirer T; Ilhan O; Mandel NM; Arat M; Günel N; Celebi H; Ustün C; Akan H; Demirer S; Aydintuğ S; Uysal A; Koç H
    Bone Marrow Transplant; 2000 Apr; 25(7):697-703. PubMed ID: 10745253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [High dose chemotherapy with thiotepa, carboplatin, VP16 and autologous stem cell transplantation in treatment of malignant brain tumors with poor prognosis. Results of a mono-center pilot study].
    Fleischhack G; Pöpping K; Hasan C; Utsch B; Jüttner J; Bode U
    Klin Padiatr; 1998; 210(4):248-55. PubMed ID: 9743961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors.
    Hara J; Osugi Y; Ohta H; Matsuda Y; Nakanishi K; Takai K; Fujisaki H; Tokimasa S; Fukuzawa M; Okada A; Okada S
    Bone Marrow Transplant; 1998 Jul; 22(1):7-12. PubMed ID: 9678789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium.
    Sandler ES; Hagg R; Coppes MJ; Mustafa MM; Gamis A; Kamani N; Wall D
    Med Pediatr Oncol; 2000 Oct; 35(4):403-9. PubMed ID: 11025470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose thiotepa and etoposide in children with poor-prognosis brain tumors.
    Fagioli F; Biasin E; Mastrodicasa L; Sandri A; Ferrero I; Berger M; Vassallo E; Madon E
    Cancer; 2004 May; 100(10):2215-21. PubMed ID: 15139067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors.
    Ozkaynak MF; Matthay K; Cairo M; Harris RE; Feig S; Reynolds CP; Buckley J; Villablanca JG; Seeger RC
    J Clin Oncol; 1998 Mar; 16(3):937-44. PubMed ID: 9508176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity of high-dose chemotherapy with etoposide, thiotepa and CY in treating poor-prognosis Ewing's sarcoma family tumors: the experience of the Bambino Gesù Children's Hospital.
    Ilari I; De Ioris MA; Milano GM; Pessolano R; De Lurentis C; De Sio L; Fidani P; Jenkner A; Cozza R
    Bone Marrow Transplant; 2010 Aug; 45(8):1274-80. PubMed ID: 20098456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group.
    Finlay JL; Goldman S; Wong MC; Cairo M; Garvin J; August C; Cohen BH; Stanley P; Zimmerman RA; Bostrom B; Geyer JR; Harris RE; Sanders J; Yates AJ; Boyett JM; Packer RJ
    J Clin Oncol; 1996 Sep; 14(9):2495-503. PubMed ID: 8823328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue.
    Grodman H; Wolfe L; Kretschmar C
    Pediatr Blood Cancer; 2009 Jul; 53(1):33-6. PubMed ID: 19326417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group.
    Grovas AC; Boyett JM; Lindsley K; Rosenblum M; Yates AJ; Finlay JL
    Med Pediatr Oncol; 1999 Aug; 33(2):83-7. PubMed ID: 10398181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease.
    Schiffman KS; Bensinger WI; Appelbaum FR; Rowley S; Lilleby K; Clift RA; Weaver CH; Demirer T; Sanders JE; Petersdorf S; Gooley T; Weiden P; Zuckerman N; Montgomery P; Maziarz R; Klarnet JP; Rivkin S; Trueblood K; Storb R; Holmberg L; Buckner CD
    Bone Marrow Transplant; 1996 Jun; 17(6):943-50. PubMed ID: 8807098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I dose-escalation study of etoposide continuous infusion added to busulphan/cyclophosphamide as conditioning prior to autologous or allogeneic stem cell transplantation.
    Ritchie DS; Szer J; Roberts AW; Shuttleworth P; Grigg AP
    Bone Marrow Transplant; 2002 Nov; 30(10):645-50. PubMed ID: 12420202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-conditioning regimen consisting of high-dose thiotepa and melphalan with autologous stem cell rescue for high-risk pediatric solid tumors: A second report.
    Okada K; Yamasaki K; Nitani C; Fujisaki H; Osugi Y; Hara J
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27953. PubMed ID: 31393093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.